Thus, limited treatment data exist for the less-studied non-PAH forms of PH. Pharmacogenomics can be a tool to better understand the pathways involved in PH, as well as to improve personalization ...

In a trial, Gossamer Bio's PAH treatment candidate seralutinib reduced the resistance blood faces moving into the lungs over ...

The PAH treatment market is projected to grow from USD 5,811.5 million in 2023 to USD 7,224.4 million by 2033, at a CAGR of 2.2%. Complementary therapies, including exercise programs and oxygen ...

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Natco Pharma gains FDA approval for generic Bosentan tablets, partnering with Lupin Pharmaceuticals for U.S. marketing.

That increase in survival is seen as a major advance in PAH treatment, which has a five-year survival rate of a little over 40%, and is backed up by functional improvements, including a ...

Five years since it launched, advances powered by the National Drug Discovery Centre are helping transform medical research in Australia and fast-tracking development of new home-grown treatments.

Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...

Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.

The researchers then tested the impact of BPTES, a commonly used GLS1 inhibitor, on PAH rats. A week after PAH was induced, ...

Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...